Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 28;51(9):1218-23.
doi: 10.3109/10826084.2016.1161054. Epub 2016 May 24.

Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs

Alice K Asher  1   2 , Carmen J Portillo  1 , Bruce A Cooper  1 , Carol Dawson-Rose  1 , David Vlahov  1 , Kimberly A Page  3
Affiliations

Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs

Alice K Asher et al. Subst Use Misuse. .

Abstract

Background: Direct-acting antivirals (DAAs) are curative in most persons with chronic hepatitis C virus (HCV) infection. However, high cost and concerns about adherence and reinfection may present continued barriers to treatment, particularly for people who inject drugs (PWID).

Objective: To understand changes in assessments of treatment candidacy, given advances in treatment.

Methods: Clinicians attending the Liver Meeting® in 2014 who reported prescribing HCV treatment in the past three years were invited to complete a survey regarding HCV treatment decisions. Participants assessed their likelihood to treat HCV in PWID in association with time of abstinence from injection drug use and what impacts their decision to provide treatment using interferon and DAAs.

Results: 108 clinicians completed the survey; 10% were willing to treat an active PWID (last injection within 30 days) using interferon-containing regimens, and 15% with all-oral regimens. For each increasing time interval of injection abstinence, there was an increase in the odds of a clinician reporting willingness to treat with DAAs (Odds Ratio (OR) 2.57, 95% CI 2.18, 3.03) and with interferon-based treatment (OR 2.22 (95% CI 1.90, 2.61), Reinfection and medication cost were cited as most important concerns when determining candidacy.

Conclusions: A cure is now the norm in HCV treatment, and there is an increasing need to address the barriers to treating PWID, the population with the highest burden of infection. Understanding treatment candidacy assessments is essential to improving uptake. This study provides insight into how clinicians view treatment candidacy in this era of DAAs and can help identify supportive treatment environments and concurrent programs.

Keywords: Hepatitis C treatment; abstinence; direct-acting antiviral hepatitis treatment candidacy; hepatitis C cure; injection drug use; people who inject drugs (PWID); providers.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

References

    1. Aghemo A, & De Francesco R (2013). New horizons in Hepatitis C antiviral therapy with direct-acting antivirals. Hepatology, 58, 428–438. - PubMed
    1. Asher A, Lum PJ, & Page K (2012). Assessing candidacy for acute hepatitis C treatment among active young injection drug users: A case-series report. Journal of the Association of Nurses in AIDS Care, 23(1), 16–29. - PMC - PubMed
    1. Backmund M, Meyer K, & Edlin BR (2004). Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clinical Infectious Diseases, 39(10), 1540–1543. - PMC - PubMed
    1. Batchelder AW, Peyser D, Nahvi S, Arnsten JH, & Litwin AH (2015). “Hepatitis C treatment turned me around:” Psychological and behavioral transformation related to hepatitis C treatment. Drug & Alcohol Dependence, 153, 66–71. - PMC - PubMed
    1. Efron B (2000). The bootstrap and modern statistics. Journal of the American Statistical Association, 95(452), 1293–1296.

Substances